Cambrex Corporation (CBM): The stock had negative money flow to the tune of ($1.43 million) on Thursday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $0.82 million, whereas, the outflow of money on downticks was $2.25 million and the ratio between the two was 0.36. The block trade had a negative net money flow of ($1.83 million). On the other hand, downticks amounted to $1.83 million of the traded value, which shows distribution in the stock by traders. Cambrex Corporation (CBM) closed with marginal gains of 21 cents to end the day at $57.47, an increase of 0.37% over the previous days close. The stock recorded 6.11% for the week.
The stock has recorded a 20-day Moving Average of 13.33% and the 50-Day Moving Average is 15.88%. Shares have rallied 18.61% from its 1 Year high price. On Nov 30, 2015, the shares registered one year high at $55.60 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $50.46 and the 200 Day Moving Average price is recorded at $44.25.
Cambrex Corporation (NYSE:CBM): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $58.25 and $57.31 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $58.71. The buying momentum continued till the end and the stock did not give up its gains. It closed at $58.00, notching a gain of 1.29% for the day. The total traded volume was 408,890 . The stock had closed at $57.26 on the previous day.
In an insider trading activity, The Securities and Exchange Commission has divulged that Korb William B, director of Cambrex Corp, had unloaded 4,142 shares at an average price of $52.47 in a transaction dated on June 8, 2016. The total value of the transaction was worth $217,331.
Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Companys customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Companys products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and, to a lesser extent, other fine chemicals. Cambrex has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment.